Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05989711 · ClinicalTrials.gov registry record · Phase 2
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study of Non-alcoholic Steatohepatitis (NASH), sponsored by Altimmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
- 20
- Study locations
NCT05989711: Completed Phase 2 study of Non-alcoholic Steatohepatitis (NASH), sponsored by Altimmune.
NCT05989711 is a Phase 2 study of Non-alcoholic Steatohepatitis (NASH) that has completed, run by Altimmune. The registered enrollment target is 212 participants, above the 183-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05989711, a Phase 2 study of Non-alcoholic Steatohepatitis (NASH), has completed, sponsored by Altimmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
- 20
- Study locations
Study Summary
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pemvidutide
Study Locations (20)
Florida
- Altimmune Clinical Study Site - Bradenton
- Altimmune Clinical Study Site - Fort Myers
- Altimmune Clinical Study Site - Hialeah Gardens
- Altimmune Clinical Study Site - Miami Lakes
- Altimmune Clinical Study Site - Port Orange
- Altimmune Clinical Study Site - Sarasota
- Altimmune Clinical Study Site - West Palm Beach
Arizona
- Altimmune Clinical Study Site - Chandler
- Altimmune Clinical Study Site - Peoria
- Altimmune Clinical Study Site - Tucson
- Altimmune Clinial Study Site - Tucson
California
- Altimmune Clinical Study Site - North Hollywood
- Altimmune Clinical Study Site - Panorama City
Georgia
- Altimmune Clinical Study Site - Dalton
- Altimmune Clinical Study Site - Marietta
Louisiana
- Altimmune Clinical Study Site - Bastrop
- Altimmune Clinical Study Site - Shreveport
Tennessee
- Altimmune Clinical Study Site - Clarksville
- Altimmune Clinical Study Site - Germantown
Colorado
- Altimmune Clinical Study Site - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2025-11-25 |
| Phase | Phase 2 |
What the finished NCT05989711 record still lists
NCT05989711 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, above the 183-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (16% higher).
The record links to 1 condition, with Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05989711 names 20 study sites across 7 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05989711 about?
NCT05989711 is a clinical study titled "IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)". Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
What is the current status of trial NCT05989711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2023-07-27. Estimated completion is 2025-11-25.
What conditions does trial NCT05989711 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis (NASH).
What interventions are being tested in trial NCT05989711?
The interventions under investigation include: Placebo (DRUG), Pemvidutide (DRUG).
Who is sponsoring clinical trial NCT05989711?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05989711 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis (NASH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05989711's enrollment target sits among peer trials
212 6th of 16 higher than 11 of 16 other Non-alcoholic Steatohepatitis (NASH) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Steatohepatitis (NASH) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
COMPLETED · Phase 2
-
Phase 2b Study in NASH to Assess IVA337
COMPLETED · Phase 2
-
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
COMPLETED · Phase 2
-
A Phase 2b Study of Icosabutate in Fatty Liver Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI